3 completed, 2 active not recruiting. 2 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Completed 2 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow Urethral Urothelial Carcinoma: new trials by email Literature Review of Urethral Urothelial Carcinoma trials Research Report on Urethral Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery Durvalumab, Therapeutic Conventional Surgery, Tremelimumab - Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 54 | 2017-03-07 | 2026-09-14 |
| Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride - Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma | Phase 1 | Completed | University of California, Davis | 32 | 2015-09-01 | 2022-10-18 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Eribulin Mesylate, Gemcitabine Hydrochloride - Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2014-12-11 | 2019-12-16 |
Urethral Neoplasms (5) · Ureteral Neoplasms (4) · Urinary Bladder Neoplasms (3) · Carcinoma, Renal Cell (1) · Hydronephrosis (1) · Penile Neoplasms (1) · Urogenital Neoplasms (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Urethral Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Ureteral Diseases (4) · Urogenital Neoplasms (4) · Urinary Bladder Diseases (3) · Kidney Diseases (2) · Adenocarcinoma (1) · Carcinoma (1)
Gemcitabine (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Biopsy (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Disulfides (1) · Docetaxel (1) · Fluorouracil (1) · Immunoglobulin G (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Mitomycin (1) · Mitozytrex (1) · Nivolumab (1) · Platinum (1)
National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · University of California, Davis (1)
United States (5) · Canada (1)
Andrea B Apolo (1) · Jianjun Gao (1) · Parminder Singh (1) · Primo Lara (1) · Sarmad Sadeghi (1)
PMID 31390274, PMID 32915679, PMID 33046869, PMID 35031545, PMID 38954785
N01CM00038 (1), P30CA016672 (1), P30CA093373 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)